Noselab’s groundbreaking diagnostic platform enables the identification of Alzheimer’s disease (AD) pathology through the simultaneous detection of AD biomarkers at the brain-nose interface (BNI) within the upper nasal cavity.
Scientific Principle
Platform Benefits
- Non-invasive
- Safe
- User-friendly
- Accessible
- Sensitive
Applications
The biomarkers of Alzheimer’s disease (AD) and other neurodegenerative diseases can be detected in the upper nasal cavity close to the skull base – an area referred to as the brain-nose interface (BNI) (fig. 1). This is facilitated by the drainage of cerebrospinal fluid (CSF) via the porous structure-cribriform plate, located at the skull base. The analysis of biomarkers in the nasal CSF (nCSF) collected from the vicinity of BNI has the potential to enable non-invasive detection of AD and other neurodegenerative diseases.
The cribriform plate forms the roof of the nasal cavity, embracing the central nervous system in the region of the olfactory bulb. Through this brain-nose interface, CSF and its biomarkers directly drain into the upper nasal cavity.